Pandemics/Epidemics (Free)
Search All Applications in Pandemics/Epidemics (Free)
Application US20160331828
Published 2016-11-17
Nucleic Acid Vaccines
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1-56. (canceled)
- 57. A nucleic acid vaccine, comprising:
one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein selected from HA1, HA7 and HA10 wherein the hemagglutinin protein is derived from a strain of Influenza A virus, wherein the RNA polynucleotide includes a chemical modification and a pharmaceutically acceptable carrier or excipient, formulated within a cationic lipid nanoparticle.
- 58. (canceled)
- 61. (canceled)
- 63. (canceled)
- 65-66. (canceled)
- 76-77. (canceled)
- 80. (canceled)
- 82-87. (canceled)
- 91-92. (canceled)
- 94-104. (canceled)
- 105. A method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one RNA polynucleotides having a single open reading frame encoding a hemagglutinin polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and wherein an adjuvant is not coformulated or co-administered with the vaccine.
- 107-131. (canceled)
